Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma Q2 Results Preview: Celgene, Amgen, Allergan And AbbVie

Executive Summary

With the FDA updating its stance on interchangeability, analysts will be pushing Amgen and AbbVie on how the policy changes will affect biosimilar competition. Celgene and Allergan will be under pressure for R&D updates; Allergan remains in the hot seat on its pipeline growth strategy from activist investors.

Advertisement

Related Content

Pfizer Agrees To Roll Back Prices On 40 Drugs, Yielding To Pressure From Trump
Attention Turns To Celgene's Other Pipeline Prospects Following Second Positive Luspatercept Read-Out
Mission Fulphila - Mylan-Biocon Biosimilar Neulasta Takes The Stage In US
US Drug Pricing Reform: No More Medicare 'Gravy Train,' Azar Tells Pharma
Amgen’s Challenge Over Sensipar Pediatric Exclusivity Moves To US Appeals Court
Celgene Shares Good News On Ozanimod, Quietly Dumps Pricey GED-0301
US Launch Of Sensipar Generics May Await Patent Case Even After FDA Approval
More Bad News: Celgene Reveals Refuse-To-File Letter For Ozanimod In MS
Celgene Admits It Screwed Up Otezla Estimates; Investors Lose Confidence
Celgene IBD Pipeline In Question As Mongersen Crohn’s Disease Trial Ends

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123458

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel